AstraZeneca Pharmaceutical

About AstraZeneca pharmaceutical

Astra Zeneca discover new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. Astra Zeneca also focus on getting the best from every medicine we make by exploring all the ways it can be used or improved.

At AstraZeneca, innovation is about more than just research. Astra Zeneca aim to stimulate continued creativity throughout their organisation by maintaining a culture in which their people feel valued, energised and rewarded for their ideas and contribution to Astra Zeneca's success - ideas which can make a difference in all aspects of our business. Astra Zeneca support and encourage their people in discovering their own potential, through excellent learning and development opportunities that are available to them throughout their careers.

With a global business comes a global responsibility for consistently high standards of behaviour worldwide. AstraZeneca aim to effectively manage that responsibility and help to find new ways of bringing benefit to society to ensure that AstraZeneca continues to be welcomed as a valued member of the global community.

AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.

There's a great deal to explore at AstraZeneca. Astra Zeneca have research and manufacturing sites in more than 25 countries, sales in over 100 and an annual turnover in excess of $21 billion. Astra Zeneca have a 64,000 strong team works across international and technical boundaries to create innovative treatments for some of the most significant and serious medical conditions.

In recent years, Astra Zeneca has had breakthroughs in all their key therapy areas including high-potential therapies for cancer, gastrointestinal disease, asthma, hypertension, high cholesterol, migraine and schizophrenia. Each of these new drugs was not only a remarkable scientific, commercial and professional achievement it was also an event that profoundly impacted on patient's quality of life.

The future looks set to be just as exciting. Every year Astra Zeneca spend $3.8 billion on researching new medicines, a level of investment that has given them one of the strongest product pipelines in the pharmaceutical industry. As new technology revolutionises the drug discovery, development and delivery process, the next few years will see a new era of growth, change and opportunity right across the Astra Zeneca business.

Latest AstraZeneca pharmaceutical news

Unable to open RSS Feed http://feeds.feedburner.com/AstraZeneca-pharmaceutical-news, exiting

AstraZeneca further information:
www.astrazeneca.co.uk / www.astrazeneca.com/ / AstraZeneca news

Page last updated: 09/06/08

Pharmaceutical product information and articles
Get the latest Pharmaceutical drug reviews, reports & pharmaceutical intelligence


Contact \| Suggest Pharmaceutical Resource	Copyright © Net Media Marketing. All rights reserved.

Pharmaceutical jobs, Medical / Pharmaceutical sales jobs, Pharmaceutical Company, Pharmaceutical, Pharmajobs, Pharma jobs, Pharmaceutical sales Pharmaceutical jobs, Healthcare sales, Laboratory sales, Veterinary sales jobs, Dental sales jobs, Trainee sales jobs, Nurse Advisor jobs, Sales Management, Pharma Marketing, Senior Management, Regulatory & Clinical & Scientific sales jobs